Why Legend Biotech stock fell 10% despite record Carvykti sales

On paper, it was another strong quarter for Carvykti. Johnson & Johnson reported record sales for the CAR-T therapy, signaling robust demand in multiple myeloma. | On paper, it was another strong quarter for Carvykti. Johnson & Johnson reported record sales for the CAR-T therapy, signaling robust demand in multiple myeloma. Yet record revenue wasn’t enough to spare its partner, Legend Biotech, from a 10% stock drop, thanks in part to comments made during J&J’s earnings call.

Raccontata dafiercepharma.com